Novartis plans bird flu vaccine plant in U.S.

05/10/2006 | MarketWatch

Novartis plans to build a vaccine plant in the U.S. that incorporates cell-based production technologies to produce avian flu vaccine quickly in case of a pandemic. Novartis CEO Daniel Vasella said the plant could cost around $400 million and may not be in production for several years. Announcement of its location could come in a few weeks, he said.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA